CIK 0001689375 · Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813983399
- Phone
- 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-16 | Dowden Nathan J President & COO | Sale 10b5-1 | −26,595 | $16.26 | $432K | 130,609 |
| 2024-08-16 | Dowden Nathan J President & COO | Sale 10b5-1 | −502 | $16.70 | $8K | 130,107 |
| 2024-08-16 | Dowden Nathan J President & COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 64,831 | ||
| 2024-07-15 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −638 | $18.00 | $11K | 188,814 |
| 2024-07-15 | Doshi Dipal CEO | Sale 10b5-1 | −1,600 | $17.81 | $28K | 334,475 |
| 2024-07-12 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −600 | $18.00 | $11K | 189,452 |
| 2024-07-12 | Doshi Dipal CEO | Sale 10b5-1 | −300 | $18.00 | $5K | 336,075 |
| 2024-07-08 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −1,758 | $14.95 | $26K | 81,412 |
| 2024-06-25 | BAKER BROS. ADVISORS LP 10% owner | Purchase · Warrants to purchase Common Stock | +285,700 | $14.85 | $4.2M | 285,700 |
| 2024-06-25 | BAKER BROS. ADVISORS LP 10% owner | Purchase · Warrants to purchase Common Stock | +3,081,303 | $14.85 | $45.8M | 3,081,303 |
| 2024-06-13 | PARMAR KUSH Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-13 | KIM PETER S Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-13 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-13 | Zeiher Bernhardt G Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-13 | Chapman Gina Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-13 | Doshi Dipal CEO | Sale 10b5-1 | −1,000 | $16.17 | $16K | 336,375 |
| 2024-06-03 | KIM PETER S Director | Option exercise | +11,918 | $6.06 | $72K | 104,330 |
| 2024-06-03 | KIM PETER S Director | Option exercise · Stock Option (Right to Buy) | −11,918 | 0 | ||
| 2024-05-20 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −9,675 | $15.19 | $147K | 190,052 |
| 2024-05-17 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −8,305 | $15.14 | $126K | 199,727 |
Page 10 of 12 · 230 trades